A prospective observational multicenter study to determine real-world effectiveness and response to adalimumab in patients with Hidradenitis suppurativa over 1-year
Latest Information Update: 02 Dec 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms SOLACE
- Sponsors AbbVie
Most Recent Events
- 02 Dec 2021 New trial record
- 01 Dec 2021 Results published in the Journal of the European Academy of Dermatology and Venereology